Comparative Pharmacology
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus ZOLADEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus ZOLADEX.
LUPRON DEPOT-PED KIT vs ZOLADEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates and then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, leading to reduced sex steroid production.
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
3.6 mg subcutaneously every 28 days (prostate cancer, endometriosis) or 10.8 mg subcutaneously every 12 weeks (prostate cancer).
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Approximately 4.2 hours (subcutaneous); due to continuous release from depot formulation, effective half-life is extended to ~28 days.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Primarily renal (approximately 20% as unchanged drug); remainder as metabolites via biliary/fecal (approximately 80%).
Category C
Category C
GnRH Agonist
GnRH Agonist